|
Dec 8
|
FDA Approves World’s First Crispr Gene-Editing Drug for Sickle-Cell Disease
|
|
Dec 8
|
Pricey new gene therapies for sickle cell pose access test
|
|
Dec 8
|
Vertex and CRISPR Therapeutics Announce US FDA Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Sickle Cell Disease
|
|
Dec 8
|
FDA approves 2 gene therapies for sickle cell. One is the first to use the editing tool CRISPR
|
|
Dec 8
|
UPDATE 1-US approves two gene therapies for sickle cell disease
|
|
Dec 8
|
CRISPR Therapeutics Just Slashed Its Staff by 10%. Should Shareholders Be Worried?
|
|
Dec 8
|
CRISPR therapy for sickle cell approved by FDA in gene editing milestone
|
|
Dec 8
|
Jim Simons Stock Portfolio: 10 Top Stock Picks
|
|
Dec 7
|
Vertex Stock Is Down. Its Painkiller Could Spark Big Gains.
|
|
Dec 7
|
This Newly Discovered Risk Could Be a Big Headache for Vertex Pharmaceuticals and CRISPR Therapeutics
|
|
Dec 7
|
5 Unstoppable Trends to Invest $1,000 in for 2024
|
|
Dec 5
|
Vertex Appoints Nancy Thornberry to its Board of Directors
|
|
Dec 4
|
GSK vs. VRTX: Which Stock Should Value Investors Buy Now?
|
|
Dec 4
|
You Don't Have to Pick a Winner in Gene-Editing. Do This Instead.
|
|
Dec 4
|
A Bull Market Is Coming. Here Are 3 Stocks You'll Absolutely Want to Own.
|
|
Dec 4
|
Where Will Vertex Pharmaceuticals Be in 10 Years?
|
|
Dec 3
|
3 No-Brainer Growth Stocks to Buy in December
|
|
Dec 3
|
Got $5,000? These Are 2 of the Best Growth Stocks to Buy Right Now
|
|
Dec 2
|
5 Top Stocks to Buy Before 2024
|
|
Dec 1
|
Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals?
|